Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Lung Neoplasms 5Head and Neck Neoplasms 3Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Gliosarcoma 2Glioblastoma 2Colonic Neoplasms 2Untreated Childhood Anaplastic Astrocytoma 1Thoracic Neoplasms 1Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC 1Skin Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Metastatic Prostate Cancer 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Nasopharyngeal Carcinoma 1Lung Diseases 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Radiotherapy 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Non-Metastatic Prostate Cancer × Gefitinib × Clear all
NCT00239291 2009-04-23

Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer

AstraZeneca

Phase 1/2 Completed
42 enrolled
Genitourinary

Non-Metastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡